Melanoma

Chicago, IL

94 Melanoma Trials near Chicago, IL

Power is an online platform that helps thousands of Melanoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Trastuzumab Deruxtecan for Cancer

Chicago, Illinois
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Pre-specified HER2 mutations will be locally assessed using NGS tests or alternative methods. Prior HER2 targeting therapy is permitted.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

102 Participants Needed

rSIFN-co for Cancer

Chicago, Illinois
This trial tests a new drug called rSIFN-co. It begins with small groups of patients to determine the safest and most effective dose. The dose is gradually increased, and patients are monitored for serious side effects.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

36 Participants Needed

²¹²Pb-DOTAM-GRPR1 for Cancer

Chicago, Illinois
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

55 Participants Needed

WTX-124 + Pembrolizumab for Solid Tumors

Chicago, Illinois
This trial tests a new medicine called WTX-124, alone and with pembrolizumab, in patients with severe forms of skin and kidney cancer. WTX-124 helps the immune system attack cancer cells, and pembrolizumab makes it easier for the immune system to see these cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

150 Participants Needed

XmAb®808 + Pembrolizumab for Advanced Cancers

Chicago, Illinois
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

60 Participants Needed

BAY3375968 + Pembrolizumab for Advanced Cancer

Chicago, Illinois
This trial is testing a new antibody treatment, BAY3375968, for people with advanced cancers. The treatment aims to improve the immune system's ability to fight cancer by reducing specific cells that suppress immune response. Researchers will study its safety, the best dose, and how well it works alone and with another cancer drug, pembrolizumab.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

129 Participants Needed

Radiation Therapy for Brain Metastasis

Chicago, Illinois
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

269 Participants Needed

NM32-2668 for Advanced Cancer

Chicago, Illinois
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

180 Participants Needed

Larotrectinib for Solid Cancers

Chicago, Illinois
This trial tests how well larotrectinib works for children and adults with advanced solid tumors that have specific gene changes. The drug blocks the actions of these genes to stop cancer growth.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

215 Participants Needed

INBRX-106 + Pembrolizumab for Lung Cancer

Chicago, Illinois
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

333 Participants Needed

Cemiplimab for Skin Cancer

Chicago, Illinois
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

369 Participants Needed

RP1 for Advanced Skin Cancer in Transplant Patients

Chicago, Illinois
This trial tests RP1, a modified virus, in organ transplant recipients with advanced skin cancer. RP1 works by killing cancer cells and boosting the immune system to fight the cancer. The HIV-1 accessory protein Vpr has been shown to induce cell cycle arrest and kill tumor cells by apoptosis.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

65 Participants Needed

mRNA Vaccine + Immunotherapy for Melanoma

Chicago, Illinois
This trial is testing if a combination of a personalized cancer vaccine (mRNA-4157) and an immune-boosting medication (pembrolizumab) can better prevent melanoma from returning in patients who have had their tumors surgically removed. Pembrolizumab has been shown to help prevent the return and spread of melanoma in patients who have had their tumors surgically removed.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

267 Participants Needed

Fianlimab + Cemiplimab for Melanoma

Evanston, Illinois
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with cemiplimab alone. These types of immunotherapy study drugs are collectively known as immune checkpoint inhibitors. Immunotherapies are treatments that use the immune system to recognize and kill cancer cells. The study is focused on participants with a type of skin cancer known as melanoma. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to cemiplimab in participants with high-risk, resectable melanoma. Participants will receive treatment before surgery, undergo resection, and then will have the option to continue treatment after resection. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug(s). * How much study drug(s) is in the blood at different times. * Whether the body makes antibodies against the study drug(s) (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life.
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

150 Participants Needed

Adoptive T Cell Therapy for Melanoma

Maywood, Illinois
Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

18 Participants Needed

Genetically Engineered Lymphocytes for Melanoma

Maywood, Illinois
This is a phase one trial to determine if genetically engineered lymphocytes can be safely delivered to patients with metastatic melanoma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

14 Participants Needed

Dabrafenib + Trametinib for Melanoma

Skokie, Illinois
This phase II trial compares the effect of dabrafenib and trametinib given continuously to given with a break in treatment (intermittent) in treating patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving dabrafenib and trametinib with intermittent dosing may be as effect as when given continuously in treating patients with stage III-IV melanoma with a BRAF mutation that cannot be removed by surgery.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

280 Participants Needed

Dinaciclib for Advanced Melanoma

Maywood, Illinois
This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

72 Participants Needed

Talimogene Laherparepvec + Pembrolizumab for Skin Cancer

Maywood, Illinois
This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

43 Participants Needed

GD2-SADA:177Lu-DOTA Complex for Small Cell Lung Cancer

Chicago, Illinois
This trial tests a new treatment for certain cancers using a two-part method. The first part finds and attaches to cancer cells, and the second part delivers radiation to kill them. It aims to see if this treatment is safe and can be tolerated by patients with Small Cell Lung Cancer, Sarcoma, and Malignant Melanoma.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:16+

60 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

Immunotherapy + SBRT for Solid Cancers

Chicago, Illinois
This trial tests a new treatment combining radiation, nivolumab, and BMS-986253 for patients with advanced cancers who haven't responded to other treatments. The goal is to find safe doses and see if this combination can help the immune system fight cancer more effectively. Nivolumab, often combined with ipilimumab, has shown promising results in improving survival rates in various cancers, including melanoma.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

50 Participants Needed

NX-1607 for Advanced Cancer

Chicago, Illinois
This trial is testing NX-1607, a new experimental drug, in adults with advanced cancers that don't respond to standard treatments. The goal is to see if NX-1607 can safely stop or reduce cancer growth, either by itself or with another drug called paclitaxel. Paclitaxel is a widely used anti-cancer drug for treating various types of solid malignant tumors including breast, ovarian, and lung cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

345 Participants Needed

TSR-022 for Cancer

Chicago, Illinois
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

463 Participants Needed

TransCon TLR7/8 Agonist + Pembrolizumab for Solid Cancers

Chicago, Illinois
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist every cycle. The primary objectives are to evaluate safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

188 Participants Needed

mRNA-2752 + Durvalumab for Advanced Cancers

Chicago, Illinois
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

134 Participants Needed

LY3410738 for Solid Tumors

Chicago, Illinois
This trial is testing a new oral drug called LY3410738 in patients with advanced solid tumors that have specific genetic mutations. The drug works by blocking abnormal enzymes to potentially stop or slow cancer growth.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

200 Participants Needed

Ifinatamab Deruxtecan for Cancer

Skokie, Illinois
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

520 Participants Needed

NBTXR3 + Radiotherapy for Cancer

Chicago, Illinois
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

145 Participants Needed

TSR-022 for Advanced Cancer

Chicago, Illinois
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

475 Participants Needed

IMC-F106C Combinations for Solid Cancers

Chicago, Illinois
This trial tests IMC-F106C, a treatment that helps the immune system target and kill cancer cells in adults with advanced cancers. It guides immune cells to attack cancer cells more effectively.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

727 Participants Needed

1234

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Melanoma clinical trials in Chicago, IL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Melanoma clinical trials in Chicago, IL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Melanoma trials in Chicago, IL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Chicago, IL for Melanoma is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Chicago, IL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Melanoma medical study in Chicago, IL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Melanoma clinical trials in Chicago, IL?

Most recently, we added IMA203 for Skin Cancer, Cemiplimab for Skin Cancer and RP2 + Nivolumab for Eye Cancer to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Illinois

Anxiety Clinical Trials in Illinois

Schizophrenia Clinical Trials in Illinois

ADHD Clinical Trials in Illinois

Bipolar Disorder Clinical Trials in Illinois

Multiple Sclerosis Clinical Trials in Illinois

Autism Clinical Trials in Illinois

Treatment Resistant Depression Clinical Trials in Illinois

Borderline Personality Disorder Clinical Trials in Illinois

Social Anxiety Disorder Clinical Trials in Illinois

Parkinson's Disease Clinical Trials in Illinois

Alzheimer's Disease Clinical Trials in Illinois

By Location

Clinical Trials near Chicago, IL

Clinical Trials near Peoria, IL

Clinical Trials near Springfield, IL

Clinical Trials near Urbana, IL

Clinical Trials near Evanston, IL

Clinical Trials near Maywood, IL

Clinical Trials near Decatur, IL

Clinical Trials near Galesburg, IL

Clinical Trials near Normal, IL

Clinical Trials near Bloomington, IL

Clinical Trials near Skokie, IL

Clinical Trials near Peru, IL

Other People Viewed

By Subject

59 Multiple Sclerosis Trials near Chicago, IL

195 Clinical Trials near Barberton, OH

Top Clinical Trials near Keesler Air Force Base, MS

Top Clinical Trials near Foothill Ranch, CA

Top Clinical Trials near Flagstaff, AZ

Top Clinical Trials near Kansas

Top Alzheimer's Disease Clinical Trials near Cleveland, OH

Top Clinical Trials near Carmel, IN

Top Clinical Trials near Castle Rock, CO

Top Depression Clinical Trials near Long Beach, CA

Top Lung Cancer Clinical Trials near Austin, TX

Top Clinical Trials near Brighton, MA

By Trial

Brain Activity Monitoring for Parkinson's Disease Speech Impairment

Coramitug for Transthyretin Amyloid Cardiomyopathy

Brain Imaging for Opioid Use Disorder

Stereotactic Ablative Radiotherapy for Early Stage Breast Cancer

Blood Flow Restriction for Peripheral Arterial Disease

Low-Sodium, High-Quality Diet for Heart Failure Prevention

Ambient Heating for Heat Stress

[C-11]NPA PET-Amphetamine for Cocaine Use Disorder

AFPᶜ³³²T Cells for Advanced Liver Cancer

A(B)VD + Nivolumab for Hodgkin's Lymphoma

Cantharidin for Common Warts

Virtual Reality for Seniors Under Spinal Anesthesia

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial